Clinical trial NCT04863222: Clinical and Radiographic Success of MTA vs Biodentine
Official title: Clinical and Radiographic Success of Mineral Trioxide Aggregate (MTA) vs Septodont Biodentine in Primary Molars in Pulpotomy and Indirect Pulp Cap Treatments
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Indirect Pulp Cap
Pulpotomy
Lead sponsor: Geisinger Clinic
Sponsor class: OTHER
First posted: 2021-04-28
Enrollment: 646
Sex: ALL
Minimum age (years): 2
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.

Detailed description: This is a interventional randomized split mouth prospective study that evaluates the clinical and radiographic success of mineral trioxide aggregate (MTA) and Biodentine as pulpotomy and indirect pulp cap (IPC) medicaments. Male and female participants ages two to twelve who need at least two quadrants of treatment will be enrolled in the trial. Participants will be treated at Geisinger Medical Center, Danville, and Geisinger Bloomsburg Hospital operating rooms for full mouth rehabilitation. Each participant must have at least two matched bilateral carious primary molars that require either pulpotomy or indirect pulp cap. Maxillary and mandibular primary first and second molars who receive pulpotomy and /or indirect pulp cap will be compared. The research will be split mouth design where the primary molar on one side will get MTA as the pulpotomy or IPC medicament and the corresponding primary on the other side will get Biodentine as the pulpotomy or IPC medicament in the same arch.

The procedures will be performed according to standards of the American Academy of Pediatric Dentistry (AAPD), by Institutional Review Board approved investigators. Data will be extracted from the electronic health record (EHR) and TigerView dental radiograph imaging software. Data will be recorded using REDCap. Clinical and radiographic follow up of patients will be every 6 months since date of procedure for 3 years. Follow up will be done at the Geisinger Pediatric Dental Clinic at Danville or Milton.

Eligibility criteria: Inclusion Criteria:

* Male or female patients ages of 2 to ≤12 years.
* Bilateral symptomatic or asymptomatic vital primary molars with caries approximating or into the pulp.
* Patient who need a pulpotomy and/or indirect pulp cap treatments in two or more quadrants.
* Parents of patients who can provide consent in English.
* Patients who need treatment in an operating room setting at Geisinger.

Exclusion Criteria:

* Pre-operative radiographic or clinical symptoms associated with irreversible pulpitis or necrotic pulp.
* Radiographs not displaying furcation region of the tooth.
* Patients with cardiac conditions who need prophylaxis for infective Endocarditis.
* Patients with any type of cancer in the past or present.
* Non-restorable molars.

Primary outcomes:
measure: Rate of clinical success in pulpotomies and indirect pulp caps
timeFrame: 4 years
measure: Rate of radiographic success in pulpotomies and indirect pulp caps
timeFrame: 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: Danville
country: United States
facility: Geisinger
state: Pennsylvania
Study officials:
affiliation: Geisinger Clinic
name: Gayatri Malik, DMD
role: PRINCIPAL_INVESTIGATOR
References: